3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
28
Phase 3
6
Phase 2/3
3
Phase NA
1
Phase 4
1
Phase 1/2
1
Phase 1
1
Status
Unknown
2
Completed
1
Sponsor Class
OTHER
35
INDUSTRY
16
NETWORK
4
OTHER_GOV
3
NIH
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
3
Conditions
Rectal Neoplasms
1
Oesophagogastric Cancer
1
Esophageal Neoplasms
1
Interventions
Bevacizumab
4
Zoledronic Acid
3
Cisplatin
3
Capecitabine
3
spartalizumab
2
anlotinib
2
Radiotherapy
2
Positron Emission Tomography Computed Tomography
2
Metformin
2
Letrozole
2
Drug Therapy
2
vosaroxin
1
venetoclax
1
tislelizumab
1
pembrolizumab
1
enzalutamide
1
empagliflozin
1
atezolizumab
1
apatinib
1
abiraterone
1
XELOX
1
Vacuum Curettage
1
Tyrosine Kinase Inhibitors
1
Tuberculin
1
Sorafenib
1
Sodium Chloride
1
S 1 (combination)
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Prednisone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2/3
×
OTHER_GOV
×
Capecitabine
×
Clear all
NCT02741856
2018-10-25
SCOPE2
Velindre NHS Trust
Phase 2/3
Unknown
584 enrolled
NCT03428529
2018-02-09
INCAGI004
Instituto Nacional de Cancer, Brazil
Phase 2/3
Completed
63 enrolled
NCT00450203
2016-12-01
ST03
Medical Research Council
Phase 2/3
Unknown
1,103 enrolled